3-iodobenzylguanidine has been researched along with spironolactone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Sato, Y; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
2 trial(s) available for 3-iodobenzylguanidine and spironolactone
| Article | Year |
|---|---|
Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Drug Therapy, Combination; Female; Heart; Heart Failure; Humans; Iodine Radioisotopes; Male; Radionuclide Imaging; Radiopharmaceuticals; Spironolactone; Stroke Volume; Sympathetic Nervous System | 2002 |
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Synergism; Echocardiography; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Spironolactone; Sympathetic Nervous System; Tetrazoles; Ventricular Function, Left; Ventricular Remodeling | 2007 |